Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results

被引：0
作者：
Linton, Kim M. [1 ,2 ]
Wahlin, Bjorn [3 ,4 ]
Leppa, Sirpa [5 ]
Morschhauser, Franck [6 ]
Elliott, Brian [7 ]
Liu, Tracy [7 ]
Stirner, Mariana Cota [8 ]
Abbas, Aqeel [7 ]
Falchi, Lorenzo [9 ]
机构：
[1] Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Manchester Canc Res Ctr, Manchester, Lancs, England
[3] Karolinska Inst, Stockholm, Sweden
[4] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland
[5] Univ Helsinki, Helsinki, Finland
[6] Univ Lille, CHU Lille, Lille, France
[7] Genmab, Princeton, NJ USA
[8] AbbVie, N Chicago, IL 60064 USA
[9] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH22-PO53
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [21] Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)
    Strati, Paolo
    Agajanian, Richy
    Lossos, Izidore S.
    Coleman, Morton
    Kridel, Robert
    Wood, Andrew
    Lesley, Robin
    Wun, Chuan-Chuan
    Stephens, Deborah M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2025, 206 (03) : 887 - 898
  • [22] Phase 1 Study of Lenalidomide and Ibrutinib in Combination with Rituximab in Relapsed and Refractory CLL and SLL
    Ujjani, Chaitra S.
    Wang, Hongkun
    Skarbnik, Alan P.
    Trivedi, Neel
    Ramzi, Pari
    Khan, Nadia
    Cheson, Bruce D.
    BLOOD, 2017, 130
  • [23] Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study
    Craig, Michael
    Hanna, Wahid T.
    Cabanillas, Fernando
    Chen, Chien-Shing
    Parasuraman, Sudha
    Neuwirth, Rachel
    O'Connor, Owen A.
    BLOOD, 2010, 116 (21) : 1153 - 1154
  • [24] Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
    Batlevi, Connie Lee
    Park, Steven I.
    Phillips, Tycel Jovelle
    Amengual, Jennifer
    Andorsky, David Jacob
    Campbell, Philip
    Mckay, Pamela
    Leonard, John Paul
    Sondhi, Manu
    Yang, Jay
    Chen, Yingxue
    O'Connor, Heather
    Slatcher, Pamela
    Morschhauser, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
    Sehn, Laurie Helen
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat Umar
    Lihou, Christine Francis
    Li, Di
    Scholz, Christian W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    M Wang
    N Fowler
    N Wagner-Bartak
    L Feng
    J Romaguera
    S S Neelapu
    F Hagemeister
    M Fanale
    Y Oki
    B Pro
    J Shah
    S Thomas
    A Younes
    C Hosing
    L Zhang
    K J Newberry
    M Desai
    N Cheng
    M Badillo
    M Bejarano
    Y Chen
    K H Young
    R Champlin
    L Kwak
    L Fayad
    Leukemia, 2013, 27 : 1902 - 1909
  • [27] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
    Wang, M.
    Fowler, N.
    Wagner-Bartak, N.
    Feng, L.
    Romaguera, J.
    Neelapu, S. S.
    Hagemeister, F.
    Fanale, M.
    Oki, Y.
    Pro, B.
    Shah, J.
    Thomas, S.
    Younes, A.
    Hosing, C.
    Zhang, L.
    Newberry, K. J.
    Desai, M.
    Cheng, N.
    Badillo, M.
    Bejarano, M.
    Chen, Y.
    Young, K. H.
    Champlin, R.
    Kwak, L.
    Fayad, L.
    LEUKEMIA, 2013, 27 (09) : 1902 - 1909
  • [28] Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial
    Catherine, Thieblemont
    Tycel, Phillips
    Herve, Ghesquieres
    Cheah, Chan Y.
    David, Cunningham
    Do, Young R.
    Tatyana, Feldman
    Robin, Gasiorowski Robin
    Wojciech, Jurczak
    Tae, Min Kim Tae M.
    Lewis, David J.
    Mariolein, Van der Poe
    Poon, Michelle L.
    Thomas, Doerr
    Nurgul, Kilavuz
    Menghui, Chen
    Mariana, Sacchi
    Martin, Hutchings
    Pieternella, Lugtenburg
    Roost, Clausen Michael
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S32
  • [29] A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma
    Patel, Krish
    Bailey, Neil
    Pagel, John M.
    BLOOD, 2020, 136
  • [30] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
12345